Female Sexual Pain Disorder

Authors

  • Krittin Naravejsakul Division of Urology, Department of Surgery, School of Medicine, University of Phayao
  • Raksit Gunphairoh Division of Urology, Department of Surgery, School of Medicine, University of Phayao
  • Tharadon Pothisa Division of Pharmacy, University of Phayao hospital, School of Medicine, University of Phayao
  • Nuntakarn Saenrak Division of Health Service Support and Development, University of Phayao hospital, School of Medicine, University of Phayao

Keywords:

female, sexual pain, sexual relationship

Abstract

Abstract

           Female sexual pain disorder, as defined in the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) as a group of diseases characterized by impairments in sexual responsiveness or pleasure. In addition, according to the definition of the International Classification of Diseases and Related Health Problem (ICD-10) also refers to a person's inability to have a sexual relationship as expected, as a result of psychological and physiological factors, or a combination of both. It may also be related to other aspects, such as interpersonal issues, socio-cultural factors, etc. The disorder can be lifelong or acquired and may occur in all situations related to sexual activity (generalized) or specific to certain situations. In order to diagnose sexual dysfunctions, it must excluded the following events such as a symptom of other psychotic disorders, such as mood disorders, anxiety disorders, etc.; a direct consequence of drugs or other addictive substances; the result of other physical causes, such as peripheral neuropathy; and the result of a serious relationship problem, like sexual partner violence, physical abuse or other factors that clearly provoke stress.

Downloads

Download data is not yet available.

References

American Psychiatric Association and American Psychiatric Association DSM-5 Task Force: Diagnostic andStatistical Manual of Mental Disorders: DSM-5, 5th ed. Washington, DC: American Psychiatric Publishing Inc 2013.

Hayes RD, Dennerstein L, Bennet C, Fairley C. What is the“true” prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? J Sex Med 2008; 5: 777.

Latthe P, Latthe M, Say L, et al. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health 2006;6:177.

Fugl-Meyer KS, Nina BS, Peterson Christina D, et al. Standard operating procedures for female genital sexual pain. J Sex Med 2013;10:83-93.

Dalley AF. The American Association of Clinical Anatomists (AACA): the other American anatomy association. Anat Rec 1999;257:154.

O’Connell HE, Sanjeevan KV, Hutson JM. Anatomy of the clitoris. J Urol 2005;174:1189.

Bachmann G, Lobo R, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67.

Manson JE, Chlebowski R, Stafanick M, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA2013;310: 1353.

Simon J, Nachtigall L, Gut R, et al. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053.

Herschorn S. Female pelvic floor anatomy: the pelvic floor, supporting structures, and pelvic organs. Rev Urol 2004;6(Suppl 5):S2-S10.

Maldonado PA, Chin K, Garcia AA, et al. Anatomic variations of pudendal nerve within pelvis and pudendal

canal: clinical applications. Am J Obstet Gynecol 2015;213(5):727e1-6.

Meston CM. Sympathetic nervous system activity and female sexual arousal. Am J Cardiol 2000;86:30-4.

Levin RJ.The physiology of sexual arousal in the human female: a recreational and procreational synthesis. Arch Sex Behav 2002;31:405.

Yang CC, Cold C, Yilmaz U, et al. Sexually responsive vascular tissue of the vulva. BJU Int 2006;97:766.

Traish AM, Botchevar E, Kim NN. Biochemical factors modulating female genital sexual arousal physiology. J Sex Med 2010;7:2925-46.

Simon JA, Goldstein I, Kim N, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause 2018;25:837.

Traish AM, Vignozzi L, Simon JA, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev 2018;6:558.

Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012;19:109-17.

Nappi RE, Seracchioli R, Salvatore S, et al. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol 2019;35:453-59.

Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health 2010;1:105-11.

Sarrel PM.Ovarian hormones and vaginal blood flow: using laser Doppler velocimetry to measure effects in a clinical trial of post-menopausal women. Int J Impot Res 1998;10(Suppl2):S91-3.

Bornstein J, Goldstein A, Stockdale C, et al. 2015 ISSVD, ISSWSH and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. Obstet Gynecol 2016;127:745-51.

Parada M, DAmours T, Amsel R, et al. Clitorodynia: a descriptive study of clitoral pain. J Sex Med 2015;12:1772-80.

Zoorob D, South M, Karram M, et al. A pilot randomized trial of levator injections versus physical therapy for treatment of pelvic floor myalgia and sexual pain. Int Urogynecol J 2015;26:845-52.

Herbenick D, Reece M, Hensel D, et al. Association of lubricant use with women’s sexual pleasure, sexual satisfaction, and genital symptoms: a prospective daily diary study. J Sex Med 2011;8:202-12.

Edwards D,Panay N. Treating vulvovaginal atrophy/ genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016;19:151.

Farrell R. ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016;127:e93-6.

Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 2015;22:950-63.

Archer DF, Labrie F, Montesino M et al: Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol 2017;174:1-8.

Labrie F, Archer D, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23(3):243-56.

Portman DJ, Goldstein SR, Kagan R. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. Climacteric 2019;22(1):65-72.

Simon JA, Altemore C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt) 2018;27(1):14-23.

Di Donato V, Schiavi M, Lacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a metaanalysis of randomized trials. Part I: Evaluation of efficacy. Maturitas Maturitas 2019;121:86-92.

Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017;92(12):1842-9.

Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J 2017;28(5):681-5.

Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health 2018;10:387-95.

Goldstein I. Hormonal factors in women’s sexual pain disorders. In: Female Sexual Pain Disorders: Evaluation and Management. Edited by A Goldstein, C Pukall and I Goldstein. Oxford, England: Wiley-Blackwell Publishing Ltd 2009; chapt 28.

Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med 2013 ;1(1):30-3.

Larish AM, Dickson RR, Kudgus RA, et al. Vaginal diazepam for nonrelaxing pelvic floor dysfunction: the pharmacokinetic profile. J Sex Med 2019;16(6):763-6.

Goldstein AT, Burrows LJ, Kellogg-Spadt S. Intralevator injection of botulinum toxin for the treatment of hypertonic pelvic floor muscle dysfunction and vestibulodynia. J Sex Med 2011;8(5):1287-90.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5thed. Washington: American Psychiatric Association; 2013.

Bergeron S, Corsini-Munt S, Aerts L, et al. Female sexual pain disorders: a review of the literature on etiology and treatment. Curr Sex Health Rep. 2015;7(3):159–69.

Pukall CF, Goldstein AT, Bergeron S, et al. Vulvodynia: definition, prevalence,impact,and pathophysiologicalfactors. J Sex Med. 2016;13(3):291–304.

Committee on Gynecologic Practice. Committee Opinion No 673: Persistent Vulvar Pain. Obstet Gynecol 2016;128(3):78–84.

Al-Abbadey M, Liossi C, Curran N, et al. Treatment of female sexual pain disorders: a systematic review. J Sex Marital Ther. 2016;42(2):99-142

Goldstein AT, Pukall CF, Brown C, et al. Vulvodynia: assessment and treatment. J Sex Med 2016;13(4):572–90.

Landry T, Bergeron S, Dupuis MJ, et al. The treatment of provoked vestibulodynia: a critical review. Clin J Pain 2008;24(2):155–71.

Sadownik LA. Etiology, diagnosis, and clinical management of vulvodynia. Int J Womens Health 2014;2;6:437-49.

Yong PJ, Sadownik L, Brotto LA. Concurrent deep-superficial dys- pareunia: prevalence, associations, and outcomes in a multidisci- plinary vulvodynia program. J Sex Med 2015;12(1):219–27.

De Andres J, Sanchis-Lopez N, Asensio-Samper JM, et al. Vulvodynia an evidence-based literature review and proposed treatment algorithm. Pain Pract 2016;16(2):204–36.

Goetsch MF. Surgery combined with muscle therapy for dyspa- reunia from vulvar vestibulitis: an observational study. J Reprod Med 2007;52(7):597–603.

Baggish MS, Miklos JR. Vulvar pain syndrome: a review. Obstet Gynecol Surv 1995;50(8):618–27.

Bergeron S, Binik Y, Khalifé S, et al. A randomized comparison of group cognitive–behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treat- ment of dyspareunia resulting from vulvar vestibulitis. Pain 2001;91(3):297–306.

Reed BD, Haefner HK, Sen A, et al. Vulvodynia inci- dence and remission rates among adult women: a 2-year follow-up study. Obstet Gynecol 2008;112:231–7.

Foster DC, Kotok MB, Huang LS, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol 2010;116(3):583–93.

Brown CS, Wan J, Bachmann G, et al. Self-management, amitriptyline, and amitripyline plus triamcinolone in the manage- ment of vulvodynia. J Womens Health (Larchmt) 2009;18(2):163– 9.

Reed BD, Caron AM, Gorenflo DW, et al. Treatment of vulvodynia with tricyclic antidepressants: efficacy and associated factors. J Low Genit Tract Dis 2006;10(4):245–51.

Pagano R, Wong S. Use of amitriptyline cream in the manage- ment of entry dyspareunia due to provoked vestibulodynia.J Low Genit Tract Dis 2012;16(4):394–7.

Leo RJ, Dewani S. A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med 2013;10(10):2497–505.

Boardman LA, Cooper AS, Blais LR, et al. Topical gaba- pentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol 2008;112(3):579–85.

Bergeron S, Khalifé S, Glazer H, et al. Surgical and behavioral treatments for vestibulodynia: two-and-one-half-year follow-up and predictors of outcome. Obstet Gynecol. 2008;111(1):159–66.

Danielsson I, Torstensson T, Brodda-Jansen G, et al. EMG biofeedback versus topical lidocaine gel: a randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet Gynecol Scand 2006;85(11):1360–7.

Zolnoun DA, Hartmann KE, Steege JF. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol 2003;102(1):84–7.

Segal D, Tifheret H, Lazer S. Submucous infiltration of betameth- asone and lidocaine in the treatment of vulvar vestibulitis. Eur J Obstet Gynecol Reprod Biol 2003;107(1):105–6.

Murina F, Tassan P, Roberti P, et al. Treatment of vulvar vestibulitis with submucous infiltrations of methylprednisolone and lidocaine. An alternative approach. J Reprod Med 2001;46(8):713–6.

McDonald JS, Rapkin AJ. Multilevel local anesthetic nerve blockgade for the treatment of generalized vulvodynia: a pilot study. J Sex Med 2012;9(11):2919–26.

Rapkin AJ, McDonald JS, Morgan M. Multilevel local anesthetic nerve blockade for the treatment of vulvar vestibulitis syndrome. Am J Obstet Gynecol 2008;198(1):41.e1–5.

Abbott J. The use of botulinum toxin in the pelvic floor for women with chronic pelvic pain-a new answer to old problems? J Minim Invasive Gynecol 2009;16(2):130–5.

Petersen CD, Giraldi A, Lundvall L, et al. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med 2009;6(9):2523–37.

Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006;108(4):915–23.

Bosso JV, Aiken MJ, Simon RA. Successful prevention of local and cutaneous hypersensitivity reactions to seminal fluid with intravaginal cromolyn. Allergy Proc 1991;12(2):113–6.

Nyirjesy P, Sobel JD, Weitz MV, et al. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo controlled study. Sex Transm Infect 2001;77(1):53–7.

Murina F, Radici G, Bianco V. Capsaicin and the treatment of vul- var vestibulitis syndrome: a valuable alternative? MedGenMed 2004;6(4):48.

Steinberg AC, Oyama IA, Rejba AE, et al. Capsaicin for the treatment of vulvar vestibulitis. Am J Obstet Gynecol 2005;192(5):1549–53.

Bouchard C, Brisson J, Fortier M, et al. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. Am J Epidemiol 2002;156(3):254–61.

Edgardh K, Abdelnoor M. Vulvar vestibulitis and risk factors: a population-based case-control study in Oslo. Acta Derm Venereol 2007;87(4):350–4.

Lee M, Morgan M, Rapkin A. Clitoral and vulvar vestibular sensa- tion in women taking 20 mcg ethinyl estradiol combined oral contraceptives: a preliminary study. J Sex Med 2011;8(1):213–8.

Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med 2013;1(1):30–3.

Goldstein A, Burrows L, Goldstein I. Can oral contraceptives cause vestibulodynia? J Sex Med 2010;7:1585–7.

Simonelli C, Eleuteri S, Petruccelli F, et al. Female sexual pain disorders: dyspareunia and vaginismus. Curr Opin Psychiatry 2014;27(6):406–12.

Reissing ED, Brown C, Lord MJ, et al. Pelvic floor muscle functioning in women with vulvar vestibulitis syndrome. J Psychosom Obstet Gynaecol 2005;26(2):107–13.

Bortolami A, Vanti C, Banchelli F, et al. Relationship between female pelvic floor dysfunction and sex- ual dysfunction: an observational study. J Sex Med 2015;12(5):1233–41.

Albrecht KB. “How-To” guide to pelvic floor muscle dysfunction. Clin Obstet Gynecol 2015;58(3):546–50.

Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil. 1998;79(7):863–72.

Haefner HK, Collins ME, Davis GD, et al. The vulvodynia guideline. J Low Genit Tract Dis 2005;9(1):40–51.

Goldfinger C, Pukall CF, Gentilcore-Saulnier E, et al. A prospective study of pelvic floor physical ther- apy: pain and psychosexual outcomes in provoked vestibulodynia. J Sex Med 2009;6(7):1955–68.

Goldfinger C, Pukall CF, Thibault-Gagnon S, et al. Effectiveness of cognitive-behavioral therapy and physical therapy for provoked vestibulodynia: a randomized pilot study. J Sex Med 2016;13(1):88–94.

Gentilcore-Saulnier E, McLean L, Goldfinger C, et al. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. J Sex Med 2010;7(2 Pt 2):1003-22.

Bergeron S, Brown C, Lord MJ, et al. Physical therapy for vulvar vestibulitis syndrome: a retrospec- tive study. J Sex Marital Ther 2002;28(3):183–92.

Glazer HI, Rodke G, Swencionis C, et al. Treatment of vulvar vestibulitis syndrome with electromyo- graphic biofeedback of pelvic floor musculature. J Reprod Med 1995;40(4):283–90.

Glazer HI. Dysesthetic vulvodynia. Long-term follow-up after treatment with surface electromyography-assisted pelvic floor muscle rehabilitation. J Reprod Med. 2000;45(10):798–802.

McKay E, Kaufman RH, Doctor U, et al. Treating vulvar vestibulitis with electromyographic biofeedback of pelvic floor musculature. J Reprod Med 2001;46(4):337–42.

Murina F, Bianco V, Radici G, et al. Transcutaneous electrical nerve stimulation to treat vestibulo- dynia: a randomised controlled trial. BJOG 2008;115(9):1165– 70.

Desrochers G, Bergeron S, Khalifé S, et al. Fear avoidance and self-efficacy in relation to pain and sexual impair- ment in women with provoked vestibulodynia. Clin J Pain 2009;25(6):520–7.

Maillé DL, Bergeron S, Lambert B. Body image in women with primary and secondary provoked vestibulodynia: a controlled study. J Sex Med 2015;12(2):505–15.

Desrochers G, Bergeron S, Landry T, et al. Do psychosexual factors play a role in the etiology of provoked vestibulodynia? A critical review. J Sex Marital Ther 2008;34(3):198–226.

Smith KB, Pukall CF. A systematic review of relationship adjust- ment and sexual satisfaction among women with provoked ves- tibulodynia. J Sex Res 2011;48(2–3):166–91.

Pâquet M, Bois K, Rosen NO, et al. Why us? perceived injustice is associated with more sexual and psychological distress in couples coping with genito-pelvic pain. J Sex Med 2016;13(1):79–87.

Jackson B, Kubzansky L, Wright R, et al. Linking perceived unfairness to physical health: the perceived unfairness model. Rev Gen Psychol 2006;10(1):21–40.

Rosenbaum TY, Barnard E, Wilhite M. Psychosexual aspects of vulvar disease. Clin Obstet Gynecol 2015;58(3):551–5.

Masheb RM, Kerns RD, Lozano C, et al. A randomized clinical trial for women with vulvodynia: cognitive- behavioral therapy vs. supportive psychotherapy. Pain 2009;141(1–2):31–40.

Desrochers G, Bergeron S, Khalifé S, et al. Provoked vestibulodynia: psychological predictors of topical and cognitive-behavioral treatment outcome. Behav Res Ther 2010;48(2):106–15.

Corsini-Munt S, Bergeron S, Rosen NO, et al. Feasibility and preliminary effectiveness of a novel cognitive- behavioral couple therapy for provoked vestibulodynia: a pilot study. J Sex Med 2014;11(10):2515–27.

Lindström S, Kvist LJ. Treatment of provoked vulvodynia in a Swedish cohort using desensitization exercises and cognitive behavioral therapy. BMC Womens Health 2015;15:108.

Weijmar Schultz WC, Gianotten WL, van der Meijden WI, et al. Behavioral approach with or without surgical intervention to the vulvar ves- tibulitis syndrome: a prospective randomized and non-randomized study. J Psychosom Obstet Gynaecol 1996;17(3):143–8.

Bishop S, Lau M, Shapiro S, et al. Mindfulness: a proposed operational definition. Clin Psychol 2004;11(3):230–41.

Brotto LA, Basson R. Group mindfulness-based therapy signifi- cantly improves sexual desire in women. Behav Res Ther 2014;57:43–54.

Brotto L, Basson R, Smith K, et al. Mindfulness-based Group therapy for women with provoked vestibulodynia. Mindfulness 2015;6(3):417–32.

Pukall C, Kandyba K, Amsel R, et al. Effectiveness of hypnosis for the treatment of vulvar vestibulitis syndrome: a preliminary investigation. J Sex Med 2007;4(2):417–25.

Downloads

Published

2022-08-31

Issue

Section

Review Article (บทความวิชาการ)